Anne Landsem
University of Tromsø
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anne Landsem.
Clinical and Experimental Immunology | 2015
Anne Landsem; Hilde Fure; Dorte Christiansen; Erik Waage Nielsen; Bjarne Østerud; Tom Eirik Mollnes; Ole-Lars Brekke
The complement system and the Toll‐like (TLR) co‐receptor CD14 play important roles in innate immunity and sepsis. Tissue factor (TF) is a key initiating component in intravascular coagulation in sepsis, and long pentraxin 3 (PTX3) enhances the lipopolysaccharide (LPS)‐induced transcription of TF. The aim of this study was to study the mechanism by which complement and CD14 affects LPS‐ and Escherichia coli (E. coli)‐induced coagulation in human blood. Fresh whole blood was anti‐coagulated with lepirudin, and incubated with ultra‐purified LPS (100 ng/ml) or with E. coli (1 × 107/ml). Inhibitors and controls included the C3 blocking peptide compstatin, an anti‐CD14 F(ab′)2 antibody and a control F(ab′)2. TF mRNA was measured using quantitative polymerase chain reaction (qPCR) and monocyte TF surface expression by flow cytometry. TF functional activity in plasma microparticles was measured using an amidolytic assay. Prothrombin fragment F 1+2 (PTF1.2) and PTX3 were measured by enzyme‐linked immunosorbent assay (ELISA). The effect of TF was examined using an anti‐TF blocking antibody. E. coli increased plasma PTF1.2 and PTX3 levels markedly. This increase was reduced by 84–>99% with compstatin, 55–97% with anti‐CD14 and > 99% with combined inhibition (P < 0·05 for all). The combined inhibition was significantly (P < 0·05) more efficient than compstatin and anti‐CD14 alone. The LPS‐ and E. coli–induced TF mRNA levels, monocyte TF surface expression and TF functional activity were reduced by > 99% (P < 0·05) with combined C3 and CD14 inhibition. LPS‐ and E. coli–induced PTF1.2 was reduced by 76–81% (P < 0·05) with anti‐TF antibody. LPS and E. coli activated the coagulation system by a complement‐ and CD14‐dependent up‐regulation of TF, leading subsequently to prothrombin activation.
Metabolic Syndrome and Related Disorders | 2015
Torunn Kristin Nestvold; Erik Waage Nielsen; Judith Krey Ludviksen; Hilde Fure; Anne Landsem; Knut Tore Lappegård
BACKGROUND Morbidly obese patients are at risk of developing insulin resistance and cardiovascular disease. Low-grade systemic inflammation is an important factor for this development. We evaluated the effect of bariatric surgery on markers of inflammation, coagulation and glucose metabolism. METHODS Ninety-seven morbidly obese patients and 17 lean subjects (control group) participated. Anthropometric measurements as well as fasting blood samples were obtained at first admission, prior to surgery, and 1 year after surgery. RESULTS At admission, the morbidly obese group had significantly elevated levels of the complement components C3 and C4 compared to the lean control group (P<0.0001). Levels of C3 and C4 dropped significantly in the morbidly obese group over time (P<0.0001), and, 1 year after the operation, levels were comparable to those of the control group. The same changes were seen for markers of inflammation (high-sensitivity C-reactive protein, tumor necrosis factor-α, interferon-γ, interleukin-1 receptor antagonist, IL-6, and IL-13), coagulation (fibrinogen and plasminogen activator inhibitor-1), and glucose metabolism (leptin and insulin). There was a positive correlation between changes in C3 and body mass index, weight, coagulation parameters, inflammatory parameters, and leptin, respectively. CONCLUSIONS Bariatric surgery in morbidly obese patients reduced weight effectively. Even more importantly, the increased levels of several risk factors associated with diabetes and cardiovascular co-morbidity normalized 1 year after surgery.
Thrombosis Research | 2016
Anne Landsem; Hilde Fure; Tom Eirik Mollnes; Erik Waage Nielsen; Ole-Lars Brekke
INTRODUCTION C1-inhibitor (C1-INH), a serine protease inhibitor in plasma plays a central role in the cross-talk among the complement, coagulation, fibrinolytic and kallikrein-kinin systems. However, previous reports indicate thrombotic risks in children following supraphysiological dosing with C1-INH. OBJECTIVE To investigate the role of supraphysiological C1-INH concentrations in clot development with and without addition of Escherichia coli (E. coli) in fresh human whole blood using thromboelastometry. MATERIALS AND METHODS Blood was collected in citrate tubes, and C1-INH (3.0 to 47.6μM) or human serum albumin (HSA) was added as a control. Activated partial thromboplastin time (aPTT) was analysed in the plasma. The analyses non-activated thromboelastometry (NATEM), extrinsic (EXTEM) or intrinsic thromboelastometry (INTEM) were performed using rotational thromboelastometry. RESULTS C1-INH increased aPTT 1.8-fold (p< 0.05), whereas HSA had no effect. C1-INH increased NATEM clotting time (CT) from 789s to 2025 s (p< 0.05) in a dose-dependent manner. C1-INH reduced the NATEM alpha angle from 47 to 28° (p<0.05) and increased the NATEM clot formation time from 261s to 595s (p< 0.05). E. coli significantly reduced the NATEM CT after 120min of incubation. C1-INH prevented E. coli-induced activation (p< 0.05). C1-INH significantly increased the INTEM CT (p< 0.05), but had no effect on EXTEM CT. C1-INH (47.6μM) significantly reduced fibrinolysis measured as NATEM and EXTEM lysis indices LI60. CONCLUSIONS Supraphysiological C1-INH concentrations have dose-dependent anticoagulant effects in human whole blood in vitro. At very high levels C1-INH also inhibits fibrinolysis.
The Journal of Infectious Diseases | 2016
Alice Gustavsen; Stig Nymo; Anne Landsem; Dorte Christiansen; Liv Ryan; Harald Husebye; Corinna Lau; Søren E. Pischke; John D. Lambris; Terje Espevik; Tom Eirik Mollnes
Background. Single inhibition of the Toll-like receptor 4 (TLR4)–MD2 complex failed in treatment of sepsis. CD14 is a coreceptor for several TLRs, including TLR4 and TLR2. The aim of this study was to investigate the effect of single TLR4-MD2 inhibition by using eritoran, compared with the effect of CD14 inhibition alone and combined with the C3 complement inhibitor compstatin (Cp40), on the bacteria-induced inflammatory response in human whole blood. Methods. Cytokines were measured by multiplex technology, and leukocyte activation markers CD11b and CD35 were measured by flow cytometry. Results. Lipopolysaccharide (LPS)–induced inflammatory markers were efficiently abolished by both anti-CD14 and eritoran. Anti-CD14 was significantly more effective than eritoran in inhibiting LPS-binding to HEK-293E cells transfected with CD14 and Escherichia coli–induced upregulation of monocyte activation markers (P < .01). Combining Cp40 with anti-CD14 was significantly more effective than combining Cp40 with eritoran in reducing E. coli–induced interleukin 6 (P < .05) and monocyte activation markers induced by both E. coli (P < .001) and Staphylococcus aureus (P < .01). Combining CP40 with anti-CD14 was more efficient than eritoran alone for 18 of 20 bacteria-induced inflammatory responses (mean P < .0001). Conclusions. Whole bacteria–induced inflammation was inhibited more efficiently by anti-CD14 than by eritoran, particularly when combined with complement inhibition. Combined CD14 and complement inhibition may prove a promising treatment strategy for bacterial sepsis.
Clinical and Experimental Immunology | 2017
Elin Storjord; J. A. Dahl; Anne Landsem; Hilde Fure; Judith Krey Ludviksen; S. Goldbeck‐Wood; B. O. Karlsen; K. S. Berg; Tom Eirik Mollnes; Erik Waage Nielsen; Ole-Lars Brekke
This study aimed to examine whether acute intermittent porphyria (AIP) is associated with systemic inflammation and whether the inflammation correlates with disease activity. A case–control study with 50 AIP cases and age‐, sex‐ and place of residence‐matched controls was performed. Plasma cytokines, insulin and C‐peptide were analysed after an overnight fast using multiplex assay. Long pentraxin‐3 (PTX3) and complement activation products (C3bc and TCC) were analysed using enzyme‐linked immunosorbent assay (ELISA). Urine porphobilinogen ratio (U‐PBG, µmol/mmol creatinine), haematological and biochemical tests were performed using routine methods. Questionnaires were used to register AIP symptoms, medication and other diseases. All 27 cytokines, chemokines and growth factors investigated were increased significantly in symptomatic AIP cases compared with controls (P < 0·0004). Hierarchical cluster analyses revealed a cluster with high visfatin levels and several highly expressed cytokines including interleukin (IL)‐17, suggesting a T helper type 17 (Th17) inflammatory response in a group of AIP cases. C3bc (P = 0·002) and serum immunoglobulin (Ig)G levels (P = 0·03) were increased significantly in cases with AIP. The U‐PBG ratio correlated positively with PTX3 (r = 0·38, P = 0·006), and with terminal complement complex (TCC) levels (r = 0·33, P = 0·02). PTX3 was a significant predictor of the biochemical disease activity marker U‐PBG in AIP cases after adjustment for potential confounders in multiple linear regression analyses (P = 0·032). Prealbumin, C‐peptide, insulin and kidney function were all decreased in the symptomatic AIP cases, but not in the asymptomatic cases. These results indicate that AIP is associated with systemic inflammation. Decreased C‐peptide levels in symptomatic AIP cases indicate that reduced insulin release is associated with enhanced disease activity and reduced kidney function.
Molecular Immunology | 2018
Per H. Nilsson; Christina Johnson; Soeren Erik Pischke; Hilde Fure; Anne Landsem; Grethe Bergseth; Camilla Schjalm; Linda M. Haugaard-Kedström; Markus Huber-Lang; Ole-Lars Brekke; Tom Eirik Mollnes
Molecular Immunology | 2017
Per H. Nilsson; Christina Johnson; Søren E. Pischke; Hilde Fure; Anne Landsem; Grethe Bergseth; Linda M. Haugaard-Kedström; Markus Huber-Lang; Ole-Lars Brekke; Tom Eirik Mollnes
Molecular Immunology | 2017
Elin Storjord; Stella Airila-Månsson; Katarzyna Karlsen; Martin Ragnar Skjerve Madsen; Jim André Dahl; Anne Landsem; Hilde Fure; Judith Krey Ludviksen; Erik Waage Nielsen; Tom Eirik Mollnes; Ole-Lars Brekke
Molecular Immunology | 2017
Dorte Christiansen; Espen Waage Skjeflo; Anne Landsem; Hilde Fure; Judith Krey Ludviksen; Jørgen Stenvik; Trent M. Woodruff; Terje Espevik; Tom Eirik Mollnes
Molecular Immunology | 2017
Bård Ove Karlsen; Hilde Fure; Anne Landsem; Steinar Johansen; Tom Eirik Mollnes; Ole-Lars Brekke